|1.||Beijnen, J H: 4 articles (09/2002 - 07/2001)|
|2.||Jimeno, J M: 4 articles (09/2002 - 07/2001)|
|3.||Scheuer, P J: 3 articles (04/2004 - 01/2000)|
|4.||Albericio, Fernando: 2 articles (05/2009 - 08/2008)|
|5.||Paz-Ares, Luis: 2 articles (03/2009 - 02/2008)|
|6.||Cuevas, Carmen: 2 articles (12/2008 - 08/2008)|
|7.||Rawat, Diwan S: 2 articles (08/2008 - 01/2006)|
|8.||Joshi, Penny: 2 articles (08/2008 - 01/2006)|
|9.||Jimeno, José: 2 articles (02/2008 - 08/2005)|
|10.||Hamann, Mark T: 2 articles (09/2007 - 12/2004)|
02/15/2008 - "A dose-escalation, phase I study evaluated the safety, pharmacokinetics, and efficacy of a weekly 1-h regimen of kahalalide F, a cyclic depsipeptide isolated from the marine mollusk Elysia rufescens, in adult patients with advanced solid tumors and no standard treatment available. "
08/01/2015 - "In this study, we characterize the population pharmacokinetics of kahalalide F (KF), a novel marine anticancer drug, after intravenous (i.v.) administration in advanced cancer patients. "
07/01/2013 - "Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors."
02/15/2008 - "Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors."
04/01/2004 - "Kahalalide F has also successfully completed the phase I program in solid tumors with evidence of activity in resistant tumors and phase II studies are under way. "
|2.||Prostatic Neoplasms (Prostate Cancer)
03/01/2005 - "Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer."
03/01/2005 - "The purpose is to determine the maximum tolerated dose, profile of adverse events, and dose-limiting toxicity of Kahalalide F (KF) in patients with androgen refractory prostate cancer. "
09/01/2002 - "Kahalalide F (KF) is a novel cyclic depsipeptide anticancer drug, which has shown anticancer activity both in vitro and in vivo especially against human prostate cancer cell lines. "
10/01/2002 - "Kahalalide F (KF) is a new anticancer agent currently in clinical trials for solid tumors, including prostate cancer. "
11/21/2001 - "Kahalalide F, the only member of the family of peptides called kahalalides, isolated from the sacoglossan mollusc Elysia rufescens and the green alga Bryopsis sp., with important bioactivity, is in clinical trials for treatment of prostate cancer. "
|3.||Breast Neoplasms (Breast Cancer)
09/01/2003 - "Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells."
11/01/2006 - "The new derivative kahalalide R was found to exert comparable or even higher cytotoxicity than the potential drug candidate kahalalide F toward the MCF7 human mammary carcinoma cell line."
10/15/2010 - "In this study, proton NMR spectroscopy-based metabolomics was applied to unravel biochemical disorders induced in human MCF7 breast cancer cells by 3 lead candidate anticancer MNPs: ascididemin (Asc), lamellarin-D (Lam-D), and kahalalide F (KF). "
|4.||Psoriasis (Pustulosis Palmaris et Plantaris)
|5.||Melanoma (Melanoma, Malignant)
03/01/2009 - "Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma."
03/01/2009 - "This phase II clinical trial evaluated the antitumour response of Kahalalide F (KF) 650 microg/m(2) given as a 1-h weekly infusion in advanced malignant melanoma patients, both untreated and those who relapsed or progressed after one line of systemic therapy. "
|3.||soblidotin (TZT 1027)
|8.||Ethanol (Ethyl Alcohol)